Europe’s First Medical Cannabis Incubator
Financing European Medical Cannabis, CBD & Hemp Companies
VANCOUVER, British Columbia, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Redfund Capital Corp (CSE: LOAN) (Frankfurt:
O3X4) (OTC: PNNRF) (Redfund or the “Company”) is pleased to announce the opening of its subsidiary First Euro Cannabis, the first
medical cannabis incubator and accelerator in Europe, financing medical cannabis, CBD and hemp companies.
Redfund’s subsidiary First Euro Cannabis will be focused on sourcing the best investments into the growing market
of companies in medical cannabis, CBD, and hemp.
Cultural differences and regulations need to be handled the right way and Redfund believes that their European team
on the ground in Switzerland and London will assist the Canadian merchant bank to provide debt financing to companies currently in
revenues or with sales in their pipelines to help jumpstart their business plans and growth organically. The new first if its kind
going-global program of First Euro Cannabis will adapt to the needs and reality of these cannabis company scale-ups, designed to
improve the chances for a successful first to market international branding launch for these companies across the pond to North
America as well.
Tomorrow November 1st the UK approves legislation allowing specialist doctors such as neurologists and
pediatricians but not general practitioners in England, Wales, and Scotland to prescribe medicinal cannabis to their patients, is
foremost to Euro Cannabis spearheading the first funding into the medical cannabis space. These new laws will undoubtedly help
patients with epilepsy, multiple sclerosis and nausea from cancer treatment if prescribed by their physicians. The stigma around
medical cannabis remains an issue in the UK even with the change in the laws.
“A bad financing decision or strategic partnership can be fatal to any company and a small bridge loan has
always been the right route to go for any company to step up to the next phase in their growth cycle. Redfund is hoping to raise
over CDN$5,000,000 for First Euro Cannabis medical cannabis projects,” stated Meris Kott, CEO.
About Redfund Capital
Redfund intends to provide debt and equity funding in the mid-to-late stages of a target company’s development
or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis,
hemp and CBD-related and healthcare-related target companies.
For further information please visit www.redfundcapital.com
For more information on Redfund Capital contact Meris Kott CEO 604.484.8989 0r
info@redfundcapital.com
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain
statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively
“forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian
laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”,
“believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions
as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release
contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate
changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated
to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as
required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not
place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information
contained herein.
